文献速递自身免疫性与大疱性皮肤病

超越皮肤:寻常型天疱疮中的B细胞、免疫耐受与治疗

Beyond the skin: B cells in pemphigus vulgaris, tolerance and treatment.
PubMed 文献 · Br J Dermatol · 2024-01-01

本文为叙述性综述,总结数百年基础研究进展如何推动寻常型天疱疮(PV)的现有与新兴疗法。PV由抗桥粒芯蛋白3和1的自身抗体致病,全球患病率为每百万人0.5至16.1人,常发于50岁以上。综述归纳B细胞在PV中的多重作用,并指出利妥昔单抗治疗后疾病常因B细胞重现而复发。

要点

  • PV是罕见自身免疫性大疱病,由抗桥粒芯蛋白3和1的自身抗体致病。
  • B细胞在PV发病中起关键作用,利妥昔单抗为B细胞清除疗法。
  • 利妥昔单抗治疗后疾病常复发,与致病B细胞重现相关。

核心结论

  • B细胞在PV发病中起关键作用,利妥昔单抗治疗革新了PV的疗效与结局。
  • PV的确切病理机制、起病机制、病程和复发机制仍不清楚。
  • 需继续研究PV发病机制以推动新疗法乃至治愈手段的开发。

研究设计与样本

  • 叙述性综述,回顾过去数百年基础研究进展。
  • 总结B细胞在PV中的发育、成熟和抗体活性等多重作用。

主要发现

  • PV由针对桥粒芯蛋白3并偶与桥粒芯蛋白1联合的自身抗体致病。
  • 全球PV患病率为每百万人0.5至16.1人,常发于50岁以上人群。
  • PV未经治疗可危及生命,并显著降低患者生活质量。
  • 利妥昔单抗治疗后疾病常复发,因相同致病B细胞重现。
  • 从骨髓B细胞生成与选择到细胞在体内迁移中的变化,多种环节参与致病。

临床怎么用

  • 利妥昔单抗作为B细胞清除疗法已用于PV治疗并改善结局。
  • 临床需关注利妥昔单抗治疗后疾病复发,与B细胞重现相关。

局限性

  • PV的确切病理机制、起病机制、病程和复发机制仍不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pemphigus vulgaris (PV) is a rare autoimmune bullous disease characterized by blistering of the skin and mucosa owing to the presence of autoantibodies against the desmosome proteins desmoglein 3 and occasionally in conjunction with desmoglein 1. Fundamental research into the pathogenesis of PV has revolutionized its treatment and outcome with rituximab, a B-cell-depleting therapy. The critical contribution of B cells to the pathogenesis of pemphigus is well accepted. However, the exact pathomechanism, mechanisms of onset, disease course and relapse remain unclear. In this narrative review, we provide an overview of the fundamental research progress that has unfolded over the past few centuries to give rise to current and emerging therapies. Furthermore, we summarize the multifaceted roles of B cells in PV, including their development, maturation and antibody activity. Finally, we explored how these various aspects of B-cell function contribute to disease pathogenesis and pave the way for innovative therapeutic interventions. Pemphigus vulgaris (PV) is a rare autoimmune disease, in which the immune system attacks itself and causes blisters on the skin and inside the mouth. This happens because the body mistakenly attacks specific proteins (called desmosomes) that keep the skin together. Globally, this disease affects anywhere from 0.5 to 16.1 people per million, often older than 50 years. PV is life-threatening when left untreated. From carrying out research as far back as the 1700s, we have made significant strides in understanding PV. For example, research has led to a new treatment with the antibody rituximab, which works by eliminating the cells of the immune system that attack desmosomes (called B cells). However, after therapy is completed, the disease often returns because the same troublesome B cells reappear. There are multiple places that are involved when the body attacks desmosomes. The problems range from the bone marrow where the B cells are made and selected to the ways these cells change as they move around the body. It takes a rare combination of these changes to switch from a normal immune system to one that causes PV. Clinicians and researchers are currently developing new treatment options to better target this skin disease. We want to emphasize that research should continue to uncover how the disease works because a better understanding promotes the development of new therapies, and perhaps even a cure. This is vital, because PV can significantly lower the quality of life of people living with this skin disease.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Strandmoe AL, Bremer J, Diercks GFH, et al. Beyond the skin: B cells in pemphigus vulgaris, tolerance and treatment. Br J Dermatol. 2024. PMID: 38504438. doi:10.1093/bjd/ljae107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。